LEVICEPT LTD

During pain awareness month, we recognize that everyone will know pain in their lifetime. For some, in some diseases, its excruciating and challenges everyday life. We are driven by our mission to develop alternate non-addictive and effective treatment options for patients suffering with chronic pain. Our large-scale Phase IIb clinical trial of #LEVI04, a novel #neurotrophin-3 inhibitor has shown great promise for the treatment of moderate to severe osteoarthritis pain and offers new hope to patients with a pressing need for alternate treatment options for their chronic pain. Being developed as a once-a-month injectable initially for the treatment of osteoarthritis pain, LEVI-04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc) designed to deliver neurotrophin homeostasis. We are evaluating our options for a larger international Phase III trials. To keep up to date visit our website www.levicept.com #pain #painawarenessmonth #chronicpain #drugdevelopment #osteoarthritis #clinicaltrial

Great to see the innovation and tenacity of our founder Simon Westbrook and the conviction of our founding investor and chairman Kevin Johnson of recognized in this Sunday Times article by Glen Keogh. Data from our Phase II study of LEVI-04 are very encouraging - Professor Philip Conaghan MD, Principal Investigator in the study said, “These results are truly exceptional and clinically meaningful in their extent. Safe and effective pain management is of critical importance in arthritis with existing treatments limited by adverse effects, addiction liabilities and poor efficacy. "In this trial, LEVI-04 has demonstrated the potential to safely harness the analgesic properties of neurotrophin-3 inhibition and offer a vital new treatment option to millions of patients in huge need. If Phase III trials replicate these results, LEVI-04 would represent a major break-through for osteoarthritis treatment, and with substantial potential in other pain indications.” We are already planning for a Phase III trial and exploring strategic options. Thanks to all everyone involved so far, not least the participants in the trial and our investors Medicxi, Advent Life Sciences, Gilde Healthcare and Pfizer Ventures. https://lnkd.in/eRypKfpW

Great to see the innovation and tenacity of our founder Simon Westbrook and the conviction of our founding investor and chairman Kevin Johnson of recognized in this Sunday Times article by Glen Keogh. Data from our Phase II study of LEVI-04 are very encouraging - Professor Philip Conaghan MD, Principal Investigator in the study said, “These results are truly exceptional and clinically meaningful in their extent. Safe and effective pain management is of critical importance in arthritis with existing treatments limited by adverse effects, addiction liabilities and poor efficacy. "In this trial, LEVI-04 has demonstrated the potential to safely harness the analgesic properties of neurotrophin-3 inhibition and offer a vital new treatment option to millions of patients in huge need. If Phase III trials replicate these results, LEVI-04 would represent a major break-through for osteoarthritis treatment, and with substantial potential in other pain indications.” We are already planning for a Phase III trial and exploring strategic options. Thanks to all everyone involved so far, not least the participants in the trial and our investors Medicxi, Advent Life Sciences, Gilde Healthcare and Pfizer Ventures. https://lnkd.in/eRypKfpW

Thanks Amy Brown for taking the time to record this video on the day we release the positive data from our PhII trial of #LEVI-04 a #neurotrophin-3 inhibitor in patients with moderate to severe #osteoarthritis. We are delighted with the results and the potential that LEVI-04 could offer as a first in class medicine with a novel mode of action with no addiction or other side effects issues. Exciting times ahead as we explore strategic options for a Phase III trial with a s.c. once a month administration. #clinicaltrial #drugdevelopment #pain

NEWS: Absolutely thrilled to announce the positive results of our Phase II clinical trial of our novel neurotrophin-3 (NT-3) Inhibitor, LEVI-04, for the treatment of patients with moderate to severe osteoarthritis. LEVI-04 is the first in a new class of NT-3 inhibitors. A novel biologic, it is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc), being developed as once-a-month injectable for the treatment of osteoarthritis and chronic pain. The multiple-arm, multi-centre, randomized, double-blind, placebo-controlled, Phase II study in >500 participants with pain due to osteoarthritis of the knee has shown significant analgesia across all primary and secondary endpoints for all doses evaluated. It was well tolerated with no increase in incidence of rapid joint deterioration compared to placebo. Professor Philip Conaghan MD, Principal Investigator and Director NIHR Leeds Biomedical Research Centre at University of Leeds and Leeds Teaching Hospitals NHS Trust, UK said, “These results are truly exceptional and clinically meaningful in their extent. Safe and effective pain management is of critical importance in arthritis with existing treatments limited by adverse effects, addiction liabilities and poor efficacy. In this trial, LEVI-04 has demonstrated the potential to safely harness the analgesic properties of neurotrophin-3 inhibition and offer a vital new treatment option to millions of patients in huge need. If Phase III trials replicate these results, LEVI-04 would represent a major break-through for osteoarthritis treatment, and with substantial potential in other pain indications.” Congratulations to our team including Chair Kevin Johnson, CEO Eliot Forster, CSO Simon Westbrook, VP Clinical Operations Claire Herholdt. Thanks to our investors Medicxi, Advent Life Sciences, Gilde Healthcare and Pfizer Ventures for your support. Read the news HERE https://lnkd.in/eKr5mkkK #biotech #drugdevelopment #chronicpain #osteoarthritis #clinicaltrial

Pain. Everyone will know pain in their lifetime. For some, in some diseases, its excruciating and challenges everyday life. Our large-scale Phase II clinical trial of LEVI-04, a novel neurotrophin-modulating biological agent is nearing completion and offers new hope to patients with a pressing need for alternate treatment options for their chronic pain. Being developed as a once-a-month injectable initially for the treatment of osteoarthritis and chronic pain, LEVI-04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc) designed to deliver neurotrophin homeostasis. The multiple arm, multicentre, prospective, randomized, double-blind, placebo-controlled, Phase II study has included more than 500 participants with pain due to osteoarthritis of the knee. #WorldHealthDay #MyHealthMyRight #biotech #drugdevelopment #chronicpain #osteoarthritis

Its a key question - What Does 2024 Hold For Biopharma? Part 2 of its new year Citeline #ScripAsks article series what leaders across the industry predict. Our CEO Eliot Forster predicts that M&A will be driven by the ongoing fundamental demand for late-stage development and commercial assets as big pharma and big biotech look to bolster portfolios in the face of looming patent expiries. Levicept looks forward to data this year from our phase II study of LEVI-04 in patients with osteoarthritis of the knee. LEVI-04 is a biological therapy (LEVI-04 [p75NTR-Fc]) being developed for the treatment of chronic pain. Watch this space! Read the ScripAsks article here - https://lnkd.in/eCKp9ZMA #biotech #drugdevelopment #chronicpain #osteoarthritis

Thanks Nuala Moran for great article in BioWorld News on Levicept and our LEVI-04 p75 neurotrophin receptor fusion protein in Phase II trials for osteoarthritis knee pain. The inventor and our founder and CSO Simon Westbrook noted "if successful, LEVI-04 has blockbuster potential as a non-opioid treatment for chronic pain." Our CEO Eliot Forster said that assuming positive phase II data, “first and foremost, we have a brand new medicine, with a new mechanism of action, in a high unmet medical need.” Adding “Once you get into large clinical trials […] that is best handled by big pharma.” Read the full article here (behind a paywall) https://lnkd.in/dfkBxptk #drugdevelopment #pain

We are pleased to announce that we have completed recruitment in our Phase II clinical trial of LEVI-04, a novel neurotrophin-modulating biological agent. Our founder and CSO, and study director Simon Westbrook noted, “The fact we completed recruitment in this large-scale Phase II in under a year is testament to physicians’ interest in our programme and patients’ pressing need for new treatment options for their chronic pain.” A once-a-month injectable for the treatment of osteoarthritis and chronic pain, LEVI-04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc) designed to deliver neurotrophin homeostasis. The multiple arm, multicentre, prospective, randomized, double-blind, placebo-controlled, Phase II study has enrolled more than 500 participants with pain due to osteoarthritis of the knee (ClinicalTrials.gov ID: NCT05618782). Top line data are expected to be announced in late first half of 2024. Read the news HERE https://lnkd.in/e4H-vQT3 #biotech #drugdevelopment #chronicpain #osteoarthritis #clinicaltrial

We are pleased to announce that we have completed recruitment in our Phase II clinical trial of LEVI-04, a novel neurotrophin-modulating biological agent. Our founder and CSO, and study director Simon Westbrook noted, “The fact we completed recruitment in this large-scale Phase II in under a year is testament to physicians’ interest in our programme and patients’ pressing need for new treatment options for their chronic pain.” A once-a-month injectable for the treatment of osteoarthritis and chronic pain, LEVI-04 is a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc) designed to deliver neurotrophin homeostasis. The multiple arm, multicentre, prospective, randomized, double-blind, placebo-controlled, Phase II study has enrolled more than 500 participants with pain due to osteoarthritis of the knee (ClinicalTrials.gov ID: NCT05618782). Top line data are expected to be announced in late first half of 2024. Read the news HERE https://lnkd.in/e4H-vQT3 #biotech #drugdevelopment #chronicpain #osteoarthritis #clinicaltrial